Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients (Vi-E)
This study has been completed.
Sponsor:
A. Manzoni Hospital
Information provided by (Responsible Party):
Simeone Andrulli, A. Manzoni Hospital
ClinicalTrials.gov Identifier:
NCT00687258
First received: May 6, 2008
Last updated: April 10, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main purpose of this longitudinal study is to point out the effect of VitabranE on the ESA resistance and on the anemia observed in HD patients undergoing EPO maintenance therapy.
As a secondary purpose we will consider the effect of VitabranE on inflammation and oxidative stress parameters as a function of the changes observed in the anemia parameters.
| Condition | Intervention | Phase |
|---|---|---|
|
Anemia |
Device: VitabranE ViE Device: APS-U (Asahi Polysulfone APS) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Evaluation Of The Impact Of A New Synthetic Vitamin E-Bonded Membrane On The Anemia And Oxidative Stress In End-Stage Renal Disease (ESRD) Patients |
Resource links provided by NLM:
Drug Information available for:
alpha-Tocopherol
Tocopherol
Vitamin E succinate
Tocopherol acetate
dl-alpha-Tocopherol
U.S. FDA Resources
Further study details as provided by A. Manzoni Hospital:
Primary Outcome Measures:
- The primary outcome measure will be the ESA resistance index, a combined variable calculated by dividing the weekly ESA dose by haemoglobin level and end-dialysis body weight. [ Time Frame: every other month ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Inflammatory status (CRP and IL-6) and oxidative stress markers (Vitamin E levels, TAC, Protein carbonyls and AOPP, AGEs). [ Time Frame: every other month ] [ Designated as safety issue: No ]
| Enrollment: | 20 |
| Study Start Date: | July 2006 |
| Study Completion Date: | July 2007 |
| Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Vitamin E-bonded polysulfone dialyzer
|
Device: VitabranE ViE
Polysulfone dialyser with vitamin E alpha-tocopherol
Other Name: Vitamin E-bonded polysulfone dialyzer
|
|
No Intervention: 2
Polysulfone dialyzer without vitamin E alpha-tocopherol
|
Device: APS-U (Asahi Polysulfone APS)
PS Polysulfone dialyser without vitamin E alpha-tocopherol
Other Name: Asahi Polysulfone APS
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female patients, aged ≥ 18, stabilized on BHD for at least 6 months.
- Clinical stability during the last 3 months.
- Serum Ferritin > 200 mg/L and Transferrin saturation >30%.
- Maintenance therapy with epoetin alfa/beta or darbepoetin alfa.
Exclusion Criteria:
One of the following condition in the last 3 months :
- acute infection
- vascular access thrombosis
- ictus cerebri
- myocardial stroke
- haemorrhage
- major surgery
- haemo-transfusion
- Haemoglobinopaty, sickle cell anemia, familial erythroblastic anemia and any other haematological disorder interfering with the aim of the study
- Malignancy
- Participation to other studies or use of EPO analogues not yet commercialized
- pharmacological dosage administration of antioxidant supplements
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00687258
Locations
| Italy | |
| Alessandro Manzoni Hospital, Nephrology and Dialysis Department | |
| Lecco, Italy, 23900 | |
Sponsors and Collaborators
A. Manzoni Hospital
Investigators
| Principal Investigator: | Francesco Locatelli, MD | Nephrology and Dialysis Department - A. Manzoni Hospital |
More Information
Publications:
| Responsible Party: | Simeone Andrulli, Simeone Andrulli, MD, A. Manzoni Hospital |
| ClinicalTrials.gov Identifier: | NCT00687258 History of Changes |
| Other Study ID Numbers: | Vit E-Rif01-1 |
| Study First Received: | May 6, 2008 |
| Last Updated: | April 10, 2012 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by A. Manzoni Hospital:
|
Anemia Oxidative Stress Erythropoietin dialyser membrane |
Vitamin E Erythropoietin responsiveness Erythropoietin resistance hemodialysis |
Additional relevant MeSH terms:
|
Anemia Kidney Diseases Kidney Failure, Chronic Hematologic Diseases Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency Vitamin E Alpha-Tocopherol Tocopherols |
Tocotrienols Vitamins Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 23, 2013